GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Cyclically Adjusted PS Ratio

Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted PS Ratio : 28.18 (As of Jun. 03, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Agios Pharmaceuticals's current share price is MXN1222.00. Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN43.37. Agios Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 28.18.

The historical rank and industry rank for Agios Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:AGIO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 12.39   Med: 20.25   Max: 51.37
Current: 30.97

During the past years, Agios Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 51.37. The lowest was 12.39. And the median was 20.25.

MEX:AGIO's Cyclically Adjusted PS Ratio is ranked worse than
88.31% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs MEX:AGIO: 30.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN3.107. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN43.37 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Agios Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 20.05 16.51 28.39

Agios Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.70 32.35 36.92 28.39 28.28

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Agios Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Agios Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1222.00/43.37
=28.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Agios Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.107/134.9266*134.9266
=3.107

Current CPI (Mar. 2025) = 134.9266.

Agios Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.556 100.684 7.446
201509 2.469 100.392 3.318
201512 2.839 99.792 3.839
201603 14.221 100.470 19.098
201606 3.400 101.688 4.511
201609 4.507 101.861 5.970
201612 11.083 101.863 14.680
201703 4.680 102.862 6.139
201706 4.387 103.349 5.727
201709 4.254 104.136 5.512
201712 3.944 104.011 5.116
201803 2.858 105.290 3.662
201806 13.758 106.317 17.460
201809 4.899 106.507 6.206
201812 10.126 105.998 12.890
201903 10.031 107.251 12.620
201906 8.577 108.070 10.709
201909 8.737 108.329 10.882
201912 -24.306 108.420 -30.248
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.304 121.301 0.338
202206 2.049 125.017 2.211
202209 1.290 125.227 1.390
202212 1.529 125.222 1.647
202303 1.829 127.348 1.938
202306 2.069 128.729 2.169
202309 2.310 129.860 2.400
202312 2.156 129.419 2.248
202403 2.410 131.776 2.468
202406 2.779 132.554 2.829
202409 3.021 133.029 3.064
202412 3.805 133.157 3.856
202503 3.107 134.927 3.107

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Agios Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.